SCHEMBL6695887

SCHEMBL6695887

COc1ccc2c(-c3ccccc3)nc(N=C(N)N)nc2c1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.67
RAD52 P43351 5/20 0.67
MAPT P10636 5/20 0.67
KMT2A Q03164 4/20 0.67
MPO P05164 4/20 0.67
MEN1 O00255 3/20 0.67
KDM4E B2RXH2 5/20 0.58
POLB P06746 3/20 0.58
HTT P42858 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.49
ADORA2A P29274 2/20 0.47
NPSR1 Q6W5P4 2/20 0.46
ACACA Q13085 1/20 0.46
SLC9A3 P48764 2/20 0.45
LMNA P02545 3/20 0.44
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6692491 0.91 KMT2A (0.67) ALDH1A1RAD52MAPTKMT2AMPO
SCHEMBL6695603 0.87 RAD52 (0.74) ALDH1A1RAD52MAPTKMT2AMPO
SCHEMBL6692415 0.84 RAD52 (0.64) ALDH1A1RAD52MAPTKMT2AMPO
SCHEMBL6695258 0.83 RAD52 (0.72) ALDH1A1RAD52MAPTKMT2AMPO
SCHEMBL6693510 0.81 RAD52 (1.00) ALDH1A1RAD52MAPTKMT2AMPO
SCHEMBL6694553 0.81 KMT2A (0.81) ALDH1A1RAD52MAPTKMT2AMPO
SCHEMBL30607075 0.80 MPO (1.00) ALDH1A1RAD52MAPTKMT2AMPO
SCHEMBL21964141 0.80 MPO (1.00) ALDH1A1RAD52MAPTKMT2AMPO
SCHEMBL6695249 0.76 KDM4E (0.71) ALDH1A1RAD52MAPTKMT2AMPO
SCHEMBL6693942 0.76 RAD52 (0.74) ALDH1A1RAD52MAPTKMT2AMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors MERCK PATENT GMBH (DE) 2004-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224965-A1 2-Guanidino-4-arylchinazolines as nhe-3 inhibitors NHERF1, SLC9A3, SLC9A1 ALDH1A1 875/4885RAD52 4856/4885MAPT 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.